148 related articles for article (PubMed ID: 27092829)
1. PD-1 Blockade in Melanoma: A Promising Start, but a Long Way to Go.
Bhatia S; Thompson JA
JAMA; 2016 Apr; 315(15):1573-5. PubMed ID: 27092829
[No Abstract] [Full Text] [Related]
2. The place of PD-1 inhibitors in melanoma management.
Bowyer S; Lorigan P
Lancet Oncol; 2015 Aug; 16(8):873-4. PubMed ID: 26115798
[No Abstract] [Full Text] [Related]
3. Pembrolizumab for melanoma- safety profile and future trends.
Daud A; Nandoskar P
Expert Opin Drug Saf; 2016 Jun; 15(6):727-9. PubMed ID: 27056241
[No Abstract] [Full Text] [Related]
4. Combining immune checkpoint inhibitors for advanced melanoma: the key to optimizing treatment outcomes?
Freeston S
J Comp Eff Res; 2016 Jul; 5(4):329-33. PubMed ID: 27331424
[No Abstract] [Full Text] [Related]
5. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
6. Setting the bar for adjuvant treatment of melanoma.
Sondak VK; Gibney GT
Lancet Oncol; 2014 May; 15(6):547-8. PubMed ID: 24745697
[No Abstract] [Full Text] [Related]
7. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy: pembrolizumab-is the writing on the wall for cancer?
Hutchinson L
Nat Rev Clin Oncol; 2015 Jul; 12(7):371. PubMed ID: 25963092
[No Abstract] [Full Text] [Related]
10. Spotlight on pembrolizumab in the treatment of advanced melanoma.
Rajakulendran T; Adam DN
Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
[TBL] [Abstract][Full Text] [Related]
11. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
12. [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
Fløe LE; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(33):. PubMed ID: 27550784
[TBL] [Abstract][Full Text] [Related]
13. A rapid response to pembrolizumab in a patient with metastatic melanoma.
Bayo Calero J; Aviñó Tarazona V
Immunotherapy; 2017 Mar; 9(3):225-228. PubMed ID: 28231724
[TBL] [Abstract][Full Text] [Related]
14. [Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].
Robert C; Mateus C
Bull Acad Natl Med; 2014 Feb; 198(2):297-308. PubMed ID: 26263705
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
Harvey NT; Millward M; Macgregor K; Bucat RP; Wood BA
Am J Dermatopathol; 2016 Dec; 38(12):e159-e162. PubMed ID: 27870733
[TBL] [Abstract][Full Text] [Related]
16. Melanoma: immune checkpoint blockade story gets better.
Bhatia S; Thompson JA
Lancet; 2014 Sep; 384(9948):1078-9. PubMed ID: 25034863
[No Abstract] [Full Text] [Related]
17. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
18. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
Maul LV; Weichenthal M; Kähler KC; Hauschild A
J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
[TBL] [Abstract][Full Text] [Related]
19. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
20. Programmed death protein 1 inhibitors making inroads in multiple cancers.
Brower V
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
[No Abstract] [Full Text] [Related]
[Next] [New Search]
